Cardiotoxicity of Carbon Monoxide in Patients Treated With Hyperbaric Oxygen Therapy

Launched by UNIVERSITY HOSPITAL, BREST · Aug 8, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of carbon monoxide (CO) poisoning on the heart in patients who have received hyperbaric oxygen therapy (HBOT). Carbon monoxide poisoning can happen at home and is a serious health risk that can lead to death. The researchers want to understand both the short-term and long-term impacts of CO on heart health in people treated with HBOT, which uses oxygen at high pressure to help patients recover from poisoning.

To participate in this study, individuals must be between the ages of 65 and 74 or 35 and 24 and have been treated for CO poisoning with HBOT at Brest University Hospital between January 2015 and December 2021. If someone is interested in joining the study, they should know that participation is entirely voluntary, and if they choose not to participate, that is perfectly fine. During the trial, participants will undergo assessments to help researchers learn more about how CO affects their heart health over time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients treated for CO poisoning with HBOT in the hyperbaric and underwater medicine department of the Brest University hospital from 2015/01/01 to 2021/12/31
• Exclusion Criteria:
• • refusal